HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years.
BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.
Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity).
BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™.
HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.
18 months
10 Years
Verifiziert 25%
Beachtung. Es besteht das Risiko, dass nicht verifizierte Mitglieder nicht Mitglieder des Teams sind
